BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Albuterol Sulfate MDI (g-Proair) is Lupin Ltd.’s first device-based inhalation product to be approved by the U.S. FDA. Based on the competitive scenario, we believe g-Proair could add $80-90 million to Lupin’s revenues on an annualised basis.
We remain positive on Lupin as it is at an inflection point for growth in the developed markets, led by niche launches.
It remains on track to: a) outperform in the domestic formulations market and b) complete remediation measures at sites under regulatory issues.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR